Journal Club - Weight loss programme to be effective in managing diabetes: DIRECT TRIAL

Published On 2022-04-21 12:15 GMT   |   Update On 2022-04-21 12:15 GMT

A recent UK study has shown that a weight loss program can lead to type 2 diabetes remission, even in individuals with a normal body mass index (BMI). This is achieved via loss of body fat, particularly in the liver and pancreas.The ReTUNE trial that is Reversal of Type 2 Diabetes Upon Normalisation of Energy Intake in Non-obese People, involved 20 people with type 2 diabetes of less than...

Login or Register to read the full article

A recent UK study has shown that a weight loss program can lead to type 2 diabetes remission, even in individuals with a normal body mass index (BMI). This is achieved via loss of body fat, particularly in the liver and pancreas.

The ReTUNE trial that is Reversal of Type 2 Diabetes Upon Normalisation of Energy Intake in Non-obese People, involved 20 people with type 2 diabetes of less than 6 year's duration and a BMI of 27 kg/m2 or lower. After 1 year, participants had lost 9% of their body weight. Their body fat decreased significantly, to the same level as controls without type 2 diabetes, and they experienced decreases in liver fat, total triglycerides, and pancreatic fat.

These findings support the theory of a personal fat threshold, above which "type 2 diabetes occurs," and "Weight loss is the first-line treatment for all with type 2 diabetes, irrespective of BMI." On the other hand, the  DiRECT trial showed that a calorie-restricted liquid diet followed by gradual food reintroduction and a weight loss maintenance program can achieve and sustain type 2 diabetes remission at 2 years in people who are overweight or obese.

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News